OtherSpecial Contribution
ASNC/SNMMI Position Statement on the Clinical Indications for Myocardial Perfusion PET
Timothy Bateman, Vasken Dilsizian, Rob Beanlands, E. Gordon DePuey, Gary Heller and David Wolinsky
Journal of Nuclear Medicine August 2016, jnumed.116.180448; DOI: https://doi.org/10.2967/jnumed.116.180448
Timothy Bateman
1 Cardiovascular Consultants, United States;
Vasken Dilsizian
2 University of Maryland School of Medicine, United States;
Rob Beanlands
3 University of Ottawa Heart Institute, Canada;
E. Gordon DePuey
4 St. Luke's - Roosevelt Hospital, United States;
Gary Heller
5 Hartford Hospital, United States;
David Wolinsky
6 Cleveland Clinic Florida, United States
This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
Journal of Nuclear Medicine
Vol. 65, Issue 4
April 1, 2024
ASNC/SNMMI Position Statement on the Clinical Indications for Myocardial Perfusion PET
Timothy Bateman, Vasken Dilsizian, Rob Beanlands, E. Gordon DePuey, Gary Heller, David Wolinsky
Journal of Nuclear Medicine Aug 2016, jnumed.116.180448; DOI: 10.2967/jnumed.116.180448
Jump to section
Related Articles
Cited By...
- Predictive Model for 82Rb Generator Bolus Times as a Function of Generator Lifetime
- Simulation of Low-Dose Protocols for Myocardial Perfusion 82Rb Imaging
- Diagnostic Performance of PET Versus SPECT Myocardial Perfusion Imaging in Patients with Smaller Left Ventricles: A Substudy of the 18F-Flurpiridaz Phase III Clinical Trial
- Phase-III Clinical Trial of Fluorine-18 Flurpiridaz Positron Emission Tomography for Evaluation of Coronary Artery Disease
- Extent of Myocardial Ischemia on Positron Emission Tomography and Survival Benefit With Early Revascularization
- Randomized Comparison of Clinical Effectiveness of Pharmacologic SPECT and PET MPI in Symptomatic CAD Patients
- Is Exercise Treadmill Time or Reduction in Myocardial Ischemia the Appropriate Primary Endpoint to Assess Success of Percutaneous Coronary Intervention in Stable Angina (ORBITA)?
- Accuracy of 82Rb PET/CT Myocardial Perfusion Imaging with Regadenoson Stress, Including 3-Year Clinical Outcomes